Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
4 and 8 mg Ondansetron ready for submission in EU (exp. Q4/08) using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Proton pump inhibitors as both anti-neoplastic agents and revertant of multidrug resistance of human tumors. More
Peg GCSF More
NNRTI as antagonists of cell proliferation and inducers of cell differentiation. More
A novel cyclized histatin-based peptide DB2-121 that is a potent new antifungal agent active against the clinically important Candida albicans and a number of other organisms. More
A fermented soymilk extract, MS-20, is in Phase II (US FDA and Taiwan DOH) and Phase III (Taiwan DOH) clinical trials for the treatment of cachexia in liver cancer patients and for reducing neutropenic fever in cancer patients undergoing chemotherapy More
CA-88 is a botanically derived auxiliary treatment that has been shown to exhibit healthful benefits for patients undergoing cancer chemotherapy and radiotherapy. More
The cultured autologous squamous epithelium, which differentiates into mucociliary epithelium after in vivo grafting, are remarkably effective in airway luminal reconstruction. More
Five compounds that inhibit ABDG2 were identified More
A pharmacogenetic method to identify candidates who are most likely to benefit from treatment with statins to reduce cancer risk, and consequently minimizing any unnecessary cost and side effects in individuals who do not benefit. More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Chemotherapy side effects
- Edema
- Metastasis
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us